Ningning Ren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ningning Ren has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Fangyu Zhou
Department of Breast Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
2 shared publications - Jiamin Ma
Department of Breast Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
2 shared publications - Mengjie Yang
Department of Breast Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
2 shared publications - Wenzhong Ji
Department of Breast Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
2 shared publications - Ningning Ren
Department of Breast Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
1 shared publication - Xiaoyi Ren
Department of Breast Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
1 shared publication
Latest Publications
- Open Access
- 3 April 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (14) , e48207
Evaluation of adverse event profiles for leuprolide and goserelin: Insights from the FDA adverse event reporting system following STROBE guidelines
Leuprolide and Goserelin, both gonadotropin-releasing hormone (GnRH) agonists, are commonly used for ovarian function suppression and the management of hormone-dependent cancers. However, systematic comparisons of their adverse event (AE) profiles based on real-world pharmacovigilance data remains limited. This study aimed to compare the safety signals associated with Leuprolide and Goserelin using the the U.S. Food and Drug Administration AE Reporting System (FAERS), thereby providing insights into their distinct AE patterns. Food and Drug Administration Adverse Event Reporting System reports from the first quarter of 2004 to the third quarter of 2024 were extracted and standardized. Disproportionality signal detection was performed using the reporting odds ratio, proportional reporting ratio, chi-square (χ 2 ) test, and Bayesian confidence propagation neural network. Significant signals were defined as reporting odds ratio lower 95% CI >1, proportional reporting ratio ≥2 with χ 2 ≥4, or Bayesian confidence propagation neural network information component (IC)-2SD >0. Key signals were compared between Leuprolide- and Goserelin-related reports. A total of 12,418,989 AE reports were identified, including 64,324 Leuprolide-related and 4253 Goserelin-related cases. Both drugs showed strong signals for “prostatic specific antigen increased” (Leuprolide: χ 2 = 84,009.65, IC-2SD = 5.42; Goserelin: χ 2 = 820.31, IC-2SD = 3.38), “blood testosterone increased” (Leuprolide: χ 2 = 22,845.52, IC-2SD = 5.56; Goserelin: χ 2 = 290.23, IC-2SD = 2.28), and “prostatic specific antigen abnormal” (Leuprolide: χ 2 = 51,615.98, IC-2SD = 6.46; Goserelin: χ 2 = 422.43, IC-2SD = 2.16). Additional strong signals, such as “prostate cancer metastatic” and “hot flush,” were consistently detected in both groups. Notably, the distribution of AEs differed between drugs, suggesting drug-specific safety patterns. Leuprolide demonstrated strong associations with AEs in “Reproductive system and breast disorders,” “Neoplastic benign and malignant conditions,” and procedure-related categories, whereas Goserelin was more strongly linked to “Endocrine disorders.” These findings highlight distinct pharmacovigilance profiles between the 2 drugs and provide clinically relevant evidence to support individualized risk monitoring in hormone-dependent cancer therapies.
- 3 April 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (14) , e48207
Open AccessEvaluation of adverse event profiles for leuprolide and goserelin: Insights from the FDA adverse event reporting system following STROBE guidelines
Leuprolide and Goserelin, both gonadotropin-releasing hormone (GnRH) agonists, are commonly used for ovarian function suppression and the management of hormone-dependent cancers. However, systematic comparisons of their adverse event (AE) profiles based on real-world pharmacovigilance data remains limited. This study aimed to compare the safety signals associated with Leuprolide and Goserelin using the the U.S. Food and Drug Administration AE Reporting System (FAERS), thereby providing insights into their distinct AE patterns. Food and Drug Administration Adverse Event Reporting System reports from the first quarter of 2004 to the third quarter of 2024 were extracted and standardized. Disproportionality signal detection was performed using the reporting odds ratio, proportional reporting ratio, chi-square (χ 2 ) test, and Bayesian confidence propagation neural network. Significant signals were defined as reporting odds ratio lower 95% CI >1, proportional reporting ratio ≥2 with χ 2 ≥4, or Bayesian confidence propagation neural network information component (IC)-2SD >0. Key signals were compared between Leuprolide- and Goserelin-related reports. A total of 12,418,989 AE reports were identified, including 64,324 Leuprolide-related and 4253 Goserelin-related cases. Both drugs showed strong signals for “prostatic specific antigen increased” (Leuprolide: χ 2 = 84,009.65, IC-2SD = 5.42; Goserelin: χ 2 = 820.31, IC-2SD = 3.38), “blood testosterone increased” (Leuprolide: χ 2 = 22,845.52, IC-2SD = 5.56; Goserelin: χ 2 = 290.23, IC-2SD = 2.28), and “prostatic specific antigen abnormal” (Leuprolide: χ 2 = 51,615.98, IC-2SD = 6.46; Goserelin: χ 2 = 422.43, IC-2SD = 2.16). Additional strong signals, such as “prostate cancer metastatic” and “hot flush,” were consistently detected in both groups. Notably, the distribution of AEs differed between drugs, suggesting drug-specific safety patterns. Leuprolide demonstrated strong associations with AEs in “Reproductive system and breast disorders,” “Neoplastic benign and malignant conditions,” and procedure-related categories, whereas Goserelin was more strongly linked to “Endocrine disorders.” These findings highlight distinct pharmacovigilance profiles between the 2 drugs and provide clinically relevant evidence to support individualized risk monitoring in hormone-dependent cancer therapies.
- Open Access
- 2 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (1) , e46929
Comparative analysis of adverse events associated with epirubicin and doxorubicin: An observational study based on FDA Adverse Event Reporting System (FAERS) following STROBE guidelines
Breast cancer has overtaken lung cancer as the leading malignant tumor affecting women in many countries. Chemotherapy is one of the key adjuvant treatments for breast cancer. Epirubicin and Doxorubicin are the cornerstone of chemotherapy regimens used in clinical practice. This research utilized data extracted from the Food and Drug Administration Adverse Event Reporting System covering the period from the first quarter of 2004 to the third quarter of 2024. We confirmed the findings using the Bayesian confidence propagation neural network. From 2004 Q1 to 2024 Q3, Food and Drug Administration Adverse Event Reporting System contained 12,418,989 adverse event reports, with 5732 linked to Epirubicin and 30,613 to Doxorubicin. Febrile neutropenia (Epirubicin: 95% CI lower bound = 10.03, IC-2SD = 3.23; Doxorubicin: 95% CI lower bound = 32.68, IC-2SD = 4.89), cardiotoxicity (Epirubicin: 95% CI lower bound = 22.41, IC-2SD = 3.99; Doxorubicin: 95% CI lower bound = 62.02, IC-2SD = 5.68) exhibited a strong association with both Epirubicin and Doxorubicin. Epirubicin was more prone to the following adverse reactions: granulocyte count decreased (Epirubicin: χ 2 = 1092.8, 95% CI lower bound = 34.48, IC-2SD = 3.4). Doxorubicin was more prone to the following adverse reactions: hepatitis b reactivation (Doxorubicin: χ 2 = 7899.99, 95% CI lower bound = 39.17, IC-2SD = 4.91). Epirubicin was mainly associated with hematological, cardiac, and hepatobiliary adverse events, while Doxorubicin showed a broader spectrum, including neoplastic disorders and infections. Based on the above differences, the clinical drug selection should be balanced by the patient’s hematological status, cardiac function and HBV carrier/infection risk.
- 2 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (1) , e46929
Open AccessComparative analysis of adverse events associated with epirubicin and doxorubicin: An observational study based on FDA Adverse Event Reporting System (FAERS) following STROBE guidelines
Breast cancer has overtaken lung cancer as the leading malignant tumor affecting women in many countries. Chemotherapy is one of the key adjuvant treatments for breast cancer. Epirubicin and Doxorubicin are the cornerstone of chemotherapy regimens used in clinical practice. This research utilized data extracted from the Food and Drug Administration Adverse Event Reporting System covering the period from the first quarter of 2004 to the third quarter of 2024. We confirmed the findings using the Bayesian confidence propagation neural network. From 2004 Q1 to 2024 Q3, Food and Drug Administration Adverse Event Reporting System contained 12,418,989 adverse event reports, with 5732 linked to Epirubicin and 30,613 to Doxorubicin. Febrile neutropenia (Epirubicin: 95% CI lower bound = 10.03, IC-2SD = 3.23; Doxorubicin: 95% CI lower bound = 32.68, IC-2SD = 4.89), cardiotoxicity (Epirubicin: 95% CI lower bound = 22.41, IC-2SD = 3.99; Doxorubicin: 95% CI lower bound = 62.02, IC-2SD = 5.68) exhibited a strong association with both Epirubicin and Doxorubicin. Epirubicin was more prone to the following adverse reactions: granulocyte count decreased (Epirubicin: χ 2 = 1092.8, 95% CI lower bound = 34.48, IC-2SD = 3.4). Doxorubicin was more prone to the following adverse reactions: hepatitis b reactivation (Doxorubicin: χ 2 = 7899.99, 95% CI lower bound = 39.17, IC-2SD = 4.91). Epirubicin was mainly associated with hematological, cardiac, and hepatobiliary adverse events, while Doxorubicin showed a broader spectrum, including neoplastic disorders and infections. Based on the above differences, the clinical drug selection should be balanced by the patient’s hematological status, cardiac function and HBV carrier/infection risk.